May 28 |
Compass Therapeutics names Thomas Schuetz as CEO
|
May 28 |
Compass Therapeutics Announces CEO Transition
|
May 23 |
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual ...
|
May 14 |
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
May 13 |
Compass Therapeutics GAAP EPS of -$0.08
|
May 13 |
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
|
Apr 25 |
Compass gains FDA Fast Track status for biliary tract cancer candidate
|
Apr 25 |
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
|
Apr 16 |
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
|
Apr 12 |
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
|